Breakthrough Science for Better Health

Passionately committed to bettering the lives of patients with kidney and cardiovascular diseases.
Learn About Us

THE FACTS

740,000 ESRD patients with hyperphosphatemia in major developed countries
>500K U.S. Dialysis Patients
~95% of CKD patients on dialysis need phosphate control
~2 Million people in U.S. with CKD and/or heart failure have hyperkalemia
Impact

Making Better Medicine For Patients In Need

We are advancing our lead product, tenapanor, for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Learn More About Our Tenapanor Programs

PIPELINE

PROGRAM
INDICATION
RESEARCH
PHASE 1
PHASE 2
PHASE 3
APPROVED
Cardiorenal Programs
Tenapanor
ESRD Hyperphosphatemia
(NHE3 Inhibitor)
RDX011
Cardiorenal Indications
(NHE3 Inhibitor)
RDX013
Hyperkalemia
(Potassium Secretagogue)
Gastrointestinal Programs
Tenapanor
IBS-C
(NHE3 Inhibitor)
RDX011
GI Indications
(NHE3 Inhibitor)